These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25152995)

  • 1. The good, the bad and the ugly of the new treatments for hepatitis C virus.
    Silva-Vidal KV; Méndez-Sánchez N
    Ann Hepatol; 2014; 13(5):574-5. PubMed ID: 25152995
    [No Abstract]   [Full Text] [Related]  

  • 2. Valuing cure: bridging cost-effectiveness and coverage decisions for hepatitis C therapy.
    Pho MT; Linas BP
    Hepatology; 2014 Jul; 60(1):12-4. PubMed ID: 24825115
    [No Abstract]   [Full Text] [Related]  

  • 3. The price of good health.
    Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 7. WHO issues guidelines on HCV amid drug cost controversy.
    Slomski A
    JAMA; 2014 Jun; 311(22):2262-3. PubMed ID: 24915242
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicine. Hepatitis C can be cured globally, but at what cost?
    Hill A; Cooke G
    Science; 2014 Jul; 345(6193):141-2. PubMed ID: 25013048
    [No Abstract]   [Full Text] [Related]  

  • 9. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
    Einecke D
    MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new era in therapy of chronic hepatitis C].
    Füessl HS
    MMW Fortschr Med; 2015 Feb; 157(2):38. PubMed ID: 25743515
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New combination therapy increases chances of recovery].
    Jäger-Becker D
    MMW Fortschr Med; 2015 Feb; 157(3):70. PubMed ID: 25743682
    [No Abstract]   [Full Text] [Related]  

  • 13. Hepatitis C genotype 1.
    Foster GR; De Silva S
    Curr Opin Infect Dis; 2014 Dec; 27(6):535-9. PubMed ID: 25304394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
    Aghemo A; De Francesco R
    Gut; 2015 Jun; 64(6):860-2. PubMed ID: 25193803
    [No Abstract]   [Full Text] [Related]  

  • 15. The high price of the new hepatitis C virus drugs.
    Steinbrook R; Redberg RF
    JAMA Intern Med; 2014 Jul; 174(7):1172. PubMed ID: 24798183
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA approvals usher in the post-interferon era in HCV.
    Sheridan C
    Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
    [No Abstract]   [Full Text] [Related]  

  • 17. [Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
    MMW Fortschr Med; 2014 Dec; 156(21-22):97. PubMed ID: 25608420
    [No Abstract]   [Full Text] [Related]  

  • 18. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
    Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 20. Sofosbuvir-ribavirin duo for chronic hepatitis C.
    Njei B
    Conn Med; 2014; 78(6):355-6. PubMed ID: 25672064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.